For many years, GIP was neglected as a therapeutic target compared with GLP-1, as it was relatively ineffective at stimulating glucose dependent insulin release in patients with type 2 diabetes (T2D) when infused continuously [4]. The gene discussed is GIP; the disease is type 2 diabetes mellitus.